Article Text

PDF

Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment
  1. Andrew Hill1,
  2. Dzintars Gotham2,
  3. Joseph Fortunak3,
  4. Jonathan Meldrum4,
  5. Isabelle Erbacher2,
  6. Manuel Martin2,
  7. Haitham Shoman2,
  8. Jacob Levi2,
  9. William G Powderly5,
  10. Mark Bower6
  1. 1Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
  2. 2Faculty of Medicine, Imperial College London, London, UK
  3. 3Chemistry and Pharmaceutical Sciences, Howard University, Washington DC, USA
  4. 4Faculty of Medical Sciences, University College London, London, UK
  5. 5Institute for Public Health, Washington University in St. Louis, St. Louis, Missouri, USA
  6. 6National Centre for HIV Malignancy, Chelsea & Westminster Hospital, London, UK
  1. Correspondence to Dzintars Gotham; dg1911{at}ic.ac.uk

Abstract

Objective To calculate sustainable generic prices for 4 tyrosine kinase inhibitors (TKIs).

Background TKIs have proven survival benefits in the treatment of several cancers, including chronic myeloid leukaemia, breast, liver, renal and lung cancer. However, current high prices are a barrier to treatment. Mass production of low-cost generic antiretrovirals has led to over 13 million people being on HIV/AIDS treatment worldwide. This analysis estimates target prices for generic TKIs, assuming similar methods of mass production.

Methods Four TKIs with patent expiry dates in the next 5 years were selected for analysis: imatinib, erlotinib, lapatinib and sorafenib. Chemistry, dosing, published data on per-kilogram pricing for commercial transactions of active pharmaceutical ingredient (API), and quotes from manufacturers were used to estimate costs of production. Analysis included costs of excipients, formulation, packaging, shipping and a 50% profit margin. Target prices were compared with current prices. Global numbers of patients eligible for treatment with each TKI were estimated.

Results API costs per kg were $347–$746 for imatinib, $2470 for erlotinib, $4671 for lapatinib, and $3000 for sorafenib. Basing on annual dose requirements, costs of formulation/packaging and a 50% profit margin, target generic prices per person-year were $128–$216 for imatinib, $240 for erlotinib, $1450 for sorafenib, and $4020 for lapatinib. Over 1 million people would be newly eligible to start treatment with these TKIs annually.

Conclusions Mass generic production of several TKIs could achieve treatment prices in the range of $128–$4020 per person-year, versus current US prices of $75161–$139 138. Generic TKIs could allow significant savings and scaling-up of treatment globally, for over 1 million eligible patients.

  • HEALTH ECONOMICS
  • ONCOLOGY
  • PUBLIC HEALTH
  • THERAPEUTICS

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

View Full Text

Statistics from Altmetric.com

Supplementary materials

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.